FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Stem Cell Res Ther / Immune response to allogeneic equine mesenchymal stromal cel...
Stem cell research & therapy2021; 12(1); 570; doi: 10.1186/s13287-021-02624-y

Immune response to allogeneic equine mesenchymal stromal cells.

Abstract: Mesenchymal stromal cells (MSCs) are believed to be hypoimmunogeneic with potential use for allogeneic administration. Bone marrow was harvested from Connemara (n = 1), Standardbred (n = 6), and Thoroughbred (n = 3) horses. MSCs were grouped by their level of expression of major histocompatibility factor II (MHC II). MSCs were then sub-grouped by those MSCs derived from universal blood donor horses. MSCs were isolated and cultured using media containing fetal bovine serum until adequate numbers were acquired. The MSCs were cultured in xenogen-free media for 48 h prior to use and during all assays. Autologous and allogeneic MSCs were then directly co-cultured with responder leukocytes from the Connemara horse in varying concentrations of MSCs to leukocytes (1:1, 1:10, and 1:100). MSCs were also cultured with complement present and heat-inactivated complement to determine whether complement alone would decrease MSC viability. MSCs underwent haplotyping of their equine leukocyte antigen (ELA) to determine whether the MHC factors were matched or mismatched between the donor MSCs and the responder leukocytes. All allogeneic MSCs were found to be ELA mismatched with the responder leukocytes. MHC II-low and universal blood donor MSCs caused no peripheral blood mononuclear cell (PBMC) proliferation, no increase in B cells, and no activation of CD8 lymphocytes. Universal blood donor MSCs stimulated a significant increase in the number of T regulatory cells. Neutrophil interaction with MSCs showed that universal blood donor and MHC II-high allogeneic MSCs at the 6 h time point in co-culture caused greater neutrophil activation than the other co-culture groups. Complement-mediated cytotoxicity did not consistently cause MSC death in cultures with active complement as compared to those with inactivated complement. Gene expression assays revealed that the universal blood donor group and the MHC II-low MSCs were more metabolically active both in the anabolic and catabolic gene categories when cultured with allogeneic lymphocytes as compared to the other co-cultures. These upregulated genes included CD59, FGF-2, HGF, IDO, IL-10, IL-RA, IL-2, SOX2, TGF-β1, ADAMSTS-4, ADAMSTS-5, CCL2, CXCLB/IL-8, IFNγ, IL-1β, and TNFα. MHC II-low MSCs are the most appropriate type of allogeneic MSC to prevent activation of the innate and cell-mediated component of the adaptive immune systems and have increased gene expression as compared to other allogeneic MSCs.
© 2021. The Author(s).
Get Full Text
Publication Date: 2021-11-12 PubMed ID: 34772445PubMed Central: PMC8588742DOI: 10.1186/s13287-021-02624-yGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research studied the immune response of horses to the allogeneic administration of mesenchymal stromal cells (MSCs) it aims to understand the suitability of different types of MSCs in allogenic therapies. The research found that MSCs having low levels of major histocompatibility factor II (MHC II) are the most appropriate for preventing immune system activation and show increased gene expression compared to other MSC types.

Research Methodology

  • The bone marrow was harvested from Connemara, Standardbred, and Thoroughbred horses.
  • The MSCs obtained were grouped by their level of major histocompatibility factor II (MHC II) expression and those that derived from universal blood donor horses.
  • The MSCs were cultured in xenogen-free media for 48 hours and during all assays.
  • The cultivated MSCs underwent various tests, including co-culturing with responder leukocytes from a Connemara horse, interaction with complement, and haplotyping of their equine leukocyte antigen (ELA).

Findings

  • All allogeneic MSCs were found to be ELA mismatched with the responder leukocytes.
  • MHC II-low and universal blood donor MSCs did not cause peripheral blood mononuclear cell (PBMC) proliferation, increase in B cells, or activation of CD8 lymphocytes.
  • Universal blood donor MSCs stimulated a significant increase in the number of T regulatory cells.
  • Neutrophil interaction with MSCs showed that universal blood donor and MHC II-high allogenic MSCs caused more neutrophil activation than the other co-culture groups.
  • The presence of complement did not consistently cause MSC death.
  • Gene expression assays showed upregulated genes in universal blood donor and MHC II-low MSCs when cultured with allogenic lymphocytes compared to other co-cultures.

Conclusion

  • MHC II-low MSCs are most suitable for allogenic administration to prevent activation of innate and cell-mediated components of adaptive immune systems.
  • These types of MSCs also show increased gene expression compared to other allogenic MSCs, suggesting better integration with the host immune system.

This research adds valuable contribution to the field, providing insights on properties of different types of MSCs when used in allogenic transplantation and thus improving therapeutic potential for different conditions.

Cite This Article

APA
Kamm JL, Riley CB, Parlane NA, Gee EK, McIlwraith CW. (2021). Immune response to allogeneic equine mesenchymal stromal cells. Stem Cell Res Ther, 12(1), 570. https://doi.org/10.1186/s13287-021-02624-y

Publication

Stem cell research & therapy
ISSN: 1757-6512
NlmUniqueID: 101527581
Country: England
Language: English
Volume: 12
Issue: 1
Pages: 570
PII: 570

Researcher Affiliations

Kamm, J Lacy
  • School of Veterinary Science, Massey University, Tennent Drive, Palmerston North, 4442, New Zealand. lacykamm@gmail.com.
Riley, Christopher B
  • School of Veterinary Science, Massey University, Tennent Drive, Palmerston North, 4442, New Zealand.
Parlane, Natalie A
  • AgResearch, Hopkirk Research Institute, Massey University, Palmerston North, 4474, New Zealand.
Gee, Erica K
  • School of Veterinary Science, Massey University, Tennent Drive, Palmerston North, 4442, New Zealand.
McIlwraith, C Wayne
  • School of Veterinary Science, Massey University, Tennent Drive, Palmerston North, 4442, New Zealand.
  • C. Wayne McIlwraith Translational Medicine Institute and the Orthopaedic Research Center, Colorado State University, 1678 Campus Delivery, Fort Collins, CO, 80523-1678, USA.

MeSH Terms

  • Animals
  • Bone Marrow Cells
  • Cells, Cultured
  • Hematopoietic Stem Cell Transplantation
  • Horses
  • Immunity
  • Leukocytes, Mononuclear
  • Mesenchymal Stem Cells / metabolism

Conflict of Interest Statement

J. Lacy Kamm and C. Wayne McIlwraith are directors in Advanced Regenerative Therapies—NZ. There are no competing interests for the other authors.

References

This article includes 65 references
  1. Ahmad E, Kingma DW, Jaffe ES, Schrager JA, Janik J, Wilson W, Stetler-Stevenson M. Flow cytometric immunophenotypic profiles of mature gamma delta T-cell malignancies involving peripheral blood and bone marrow.. Cytometry B Clin Cytom 2005 Sep;67(1):6-12.
    doi: 10.1002/cyto.b.20063pubmed: 15973700google scholar: lookup
  2. Alagesan S, Sanz-Nogués C, Chen X, Creane M, Ritter T, Ceredig R, O'Brien T, Griffin MD. Anti-donor antibody induction following intramuscular injections of allogeneic mesenchymal stromal cells.. Immunol Cell Biol 2018 May;96(5):536-548.
    doi: 10.1111/imcb.12024pubmed: 29446493google scholar: lookup
  3. Amable PR, Teixeira MV, Carias RB, Granjeiro JM, Borojevic R. Mesenchymal stromal cell proliferation, gene expression and protein production in human platelet-rich plasma-supplemented media.. PLoS One 2014;9(8):e104662.
    doi: 10.1371/journal.pone.0104662pmc: PMC4130592pubmed: 25115920google scholar: lookup
  4. Ardanaz N, Vázquez FJ, Romero A, Remacha AR, Barrachina L, Sanz A, Ranera B, Vitoria A, Albareda J, Prades M, Zaragoza P, Martín-Burriel I, Rodellar C. Inflammatory response to the administration of mesenchymal stem cells in an equine experimental model: effect of autologous, and single and repeat doses of pooled allogeneic cells in healthy joints.. BMC Vet Res 2016 Mar 31;12:65.
    doi: 10.1186/s12917-016-0692-xpmc: PMC4815220pubmed: 27029614google scholar: lookup
  5. Arzi B, Clark KC, Sundaram A, Spriet M, Verstraete FJM, Walker NJ, Loscar MR, Fazel N, Murphy WJ, Vapniarsky N, Borjesson DL. Therapeutic Efficacy of Fresh, Allogeneic Mesenchymal Stem Cells for Severe Refractory Feline Chronic Gingivostomatitis.. Stem Cells Transl Med 2017 Aug;6(8):1710-1722.
    doi: 10.1002/sctm.17-0035pmc: PMC5689767pubmed: 28618186google scholar: lookup
  6. Asari S, Itakura S, Ferreri K, Liu CP, Kuroda Y, Kandeel F, Mullen Y. Mesenchymal stem cells suppress B-cell terminal differentiation.. Exp Hematol 2009 May;37(5):604-15.
    doi: 10.1016/j.exphem.2009.01.005pmc: PMC2747661pubmed: 19375651google scholar: lookup
  7. Barrachina L, Cequier A, Romero A, Vitoria A, Zaragoza P, Vázquez FJ, Rodellar C. Allo-antibody production after intraarticular administration of mesenchymal stem cells (MSCs) in an equine osteoarthritis model: effect of repeated administration, MSC inflammatory stimulation, and equine leukocyte antigen (ELA) compatibility.. Stem Cell Res Ther 2020 Feb 7;11(1):52.
    doi: 10.1186/s13287-020-1571-8pmc: PMC7006079pubmed: 32028995google scholar: lookup
  8. Berglund AK, Schnabel LV. Allogeneic major histocompatibility complex-mismatched equine bone marrow-derived mesenchymal stem cells are targeted for death by cytotoxic anti-major histocompatibility complex antibodies.. Equine Vet J 2017 Jul;49(4):539-544.
    doi: 10.1111/evj.12647pmc: PMC5425313pubmed: 27862236google scholar: lookup
  9. Bergseth G, Ludviksen JK, Kirschfink M, Giclas PC, Nilsson B, Mollnes TE. An international serum standard for application in assays to detect human complement activation products.. Mol Immunol 2013 Dec 15;56(3):232-9.
    doi: 10.1016/j.molimm.2013.05.221pubmed: 23787367google scholar: lookup
  10. Braid LR, Wood CA, Wiese DM, Ford BN. Intramuscular administration potentiates extended dwell time of mesenchymal stromal cells compared to other routes.. Cytotherapy 2018 Feb;20(2):232-244.
    doi: 10.1016/j.jcyt.2017.09.013pubmed: 29167063google scholar: lookup
  11. Cassano JM, Schnabel LV, Goodale MB, Fortier LA. Inflammatory licensed equine MSCs are chondroprotective and exhibit enhanced immunomodulation in an inflammatory environment.. Stem Cell Res Ther 2018 Apr 3;9(1):82.
    doi: 10.1186/s13287-018-0840-2pmc: PMC5883371pubmed: 29615127google scholar: lookup
  12. Carrade DD, Owens SD, Galuppo LD, Vidal MA, Ferraro GL, Librach F, Buerchler S, Friedman MS, Walker NJ, Borjesson DL. Clinicopathologic findings following intra-articular injection of autologous and allogeneic placentally derived equine mesenchymal stem cells in horses.. Cytotherapy 2011 Apr;13(4):419-30.
    doi: 10.3109/14653249.2010.536213pubmed: 21105841google scholar: lookup
  13. Carreras-Planella L, Monguió-Tortajada M, Borràs FE, Franquesa M. Corrigendum: Immunomodulatory Effect of MSC on B Cells Is Independent of Secreted Extracellular Vesicles.. Front Immunol 2019;10:2413.
    doi: 10.3389/fimmu.2019.01288pmc: PMC6803806pubmed: 31660058google scholar: lookup
  14. Colbath AC, Dow SW, Hopkins LS, Phillips JN, McIlwraith CW, Goodrich LR. Allogeneic vs. autologous intra-articular mesenchymal stem cell injection within normal horses: Clinical and cytological comparisons suggest safety.. Equine Vet J 2020 Jan;52(1):144-151.
    doi: 10.1111/evj.13136pubmed: 31120574google scholar: lookup
  15. Comoli P, Ginevri F, Maccario R, Avanzini MA, Marconi M, Groff A, Cometa A, Cioni M, Porretti L, Barberi W, Frassoni F, Locatelli F. Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation.. Nephrol Dial Transplant 2008 Apr;23(4):1196-202.
    doi: 10.1093/ndt/gfm740pubmed: 18029377google scholar: lookup
  16. Consentius C, Reinke P, Volk HD. Immunogenicity of allogeneic mesenchymal stromal cells: what has been seen in vitro and in vivo?. Regen Med 2015;10(3):305-15.
    doi: 10.2217/rme.15.14pubmed: 25933239google scholar: lookup
  17. Contreras-Kallens P, Terraza C, Oyarce K, Gajardo T, Campos-Mora M, Barroilhet MT, Álvarez C, Fuentes R, Figueroa F, Khoury M, Pino-Lagos K. Mesenchymal stem cells and their immunosuppressive role in transplantation tolerance.. Ann N Y Acad Sci 2018 Apr;1417(1):35-56.
    doi: 10.1111/nyas.13364pubmed: 28700815google scholar: lookup
  18. de Grauw JC, van de Lest CH, van Weeren PR. Inflammatory mediators and cartilage biomarkers in synovial fluid after a single inflammatory insult: a longitudinal experimental study.. Arthritis Res Ther 2009;11(2):R35.
    doi: 10.1186/ar2640pmc: PMC2688180pubmed: 19272138google scholar: lookup
  19. Delco ML, Goodale M, Talts JF, Pownder SL, Koff MF, Miller AD, Nixon B, Bonassar LJ, Lundgren-Åkerlund E, Fortier LA. Integrin α10β1-Selected Mesenchymal Stem Cells Mitigate the Progression of Osteoarthritis in an Equine Talar Impact Model.. Am J Sports Med 2020 Mar;48(3):612-623.
    doi: 10.1177/0363546519899087pubmed: 32004077google scholar: lookup
  20. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.. Blood 2002 May 15;99(10):3838-43.
    doi: 10.1182/blood.V99.10.3838pubmed: 11986244google scholar: lookup
  21. Duffy MM, Ritter T, Ceredig R, Griffin MD. Mesenchymal stem cell effects on T-cell effector pathways.. Stem Cell Res Ther 2011 Aug 11;2(4):34.
    doi: 10.1186/scrt75pmc: PMC3219065pubmed: 21861858google scholar: lookup
  22. Duffy MM, Pindjakova J, Hanley SA, McCarthy C, Weidhofer GA, Sweeney EM, English K, Shaw G, Murphy JM, Barry FP, Mahon BP, Belton O, Ceredig R, Griffin MD. Mesenchymal stem cell inhibition of T-helper 17 cell- differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor.. Eur J Immunol 2011 Oct;41(10):2840-51.
    doi: 10.1002/eji.201141499pubmed: 21710489google scholar: lookup
  23. Franquesa M, Hoogduijn MJ, Bestard O, Grinyó JM. Immunomodulatory effect of mesenchymal stem cells on B cells.. Front Immunol 2012;3:212.
    doi: 10.3389/fimmu.2012.00212pmc: PMC3400888pubmed: 22833744google scholar: lookup
  24. Ge W, Jiang J, Arp J, Liu W, Garcia B, Wang H. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression.. Transplantation 2010 Dec 27;90(12):1312-20.
    doi: 10.1097/TP.0b013e3181fed001pubmed: 21042238google scholar: lookup
  25. Ge W, Jiang J, Baroja ML, Arp J, Zassoko R, Liu W, Bartholomew A, Garcia B, Wang H. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance.. Am J Transplant 2009 Aug;9(8):1760-72.
    doi: 10.1111/j.1600-6143.2009.02721.xpubmed: 19563344google scholar: lookup
  26. Gnecchi M, Cervio E. Mesenchymal stem cell therapy for heart disease. In: Chase LG, Vemuri MC, editors. Mesenchymal stem cell therapy. Totowa: Humana Press; 2013. p. 241.
  27. Griffin MD, Ryan AE, Alagesan S, Lohan P, Treacy O, Ritter T. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far?. Immunol Cell Biol 2013 Jan;91(1):40-51.
    doi: 10.1038/icb.2012.67pubmed: 23207278google scholar: lookup
  28. Hamza E, Gerber V, Steinbach F, Marti E. Equine CD4(+) CD25(high) T cells exhibit regulatory activity by close contact and cytokine-dependent mechanisms in vitro.. Immunology 2011 Nov;134(3):292-304.
    doi: 10.1111/j.1365-2567.2011.03489.xpmc: PMC3209569pubmed: 21977999google scholar: lookup
  29. Hardy J. Venous and arterial catheterization and fluid therapy. In: Muir WW, Hubbell JA, editors. Equine anesthesia: monitoring and emergency therapy. 2. Missouri: Mosby Elsevier; 2009.
  30. Hill JA, Cassano JM, Goodale MB, Fortier LA. Antigenicity of mesenchymal stem cells in an inflamed joint environment.. Am J Vet Res 2017 Jul;78(7):867-875.
    doi: 10.2460/ajvr.78.7.867pubmed: 28650243google scholar: lookup
  31. Holmes CM, Violette N, Miller D, Wagner B, Svansson V, Antczak DF. MHC haplotype diversity in Icelandic horses determined by polymorphic microsatellites.. Genes Immun 2019 Nov;20(8):660-670.
    doi: 10.1038/s41435-0190075-ypubmed: 31068686google scholar: lookup
  32. Huang XP, Ludke A, Dhingra S, Guo J, Sun Z, Zhang L, Weisel RD, Li RK. Class II transactivator knockdown limits major histocompatibility complex II expression, diminishes immune rejection, and improves survival of allogeneic bone marrow stem cells in the infarcted heart.. FASEB J 2016 Sep;30(9):3069-82.
    doi: 10.1096/fj.201600331Rpubmed: 27221978google scholar: lookup
  33. Joel MDM, Yuan J, Wang J, Yan Y, Qian H, Zhang X, Xu W, Mao F. MSC: immunoregulatory effects, roles on neutrophils and evolving clinical potentials.. Am J Transl Res 2019;11(6):3890-3904.
    pmc: PMC6614638pubmed: 31312397
  34. Joswig AJ, Mitchell A, Cummings KJ, Levine GJ, Gregory CA, Smith R 3rd, Watts AE. Repeated intra-articular injection of allogeneic mesenchymal stem cells causes an adverse response compared to autologous cells in the equine model.. Stem Cell Res Ther 2017 Feb 28;8(1):42.
    doi: 10.1186/s13287-017-0503-8pmc: PMC5329965pubmed: 28241885google scholar: lookup
  35. Kamm JL, Parlane NA, Riley CB, Gee EK, Dittmer KE, McIlwraith CW. Blood type and breed-associated differences in cell marker expression on equine bone marrow-derived mesenchymal stem cells including major histocompatibility complex class II antigen expression.. PLoS One 2019;14(11):e0225161.
    doi: 10.1371/journal.pone.0225161pmc: PMC6867698pubmed: 31747418google scholar: lookup
  36. Kamm JL, Nixon AJ, Witte TH. Cytokine and catabolic enzyme expression in synovium, synovial fluid and articular cartilage of naturally osteoarthritic equine carpi.. Equine Vet J 2010 Nov;42(8):693-9.
    doi: 10.1111/j.2042-3306.2010.00140.xpmc: PMC4183755pubmed: 21039798google scholar: lookup
  37. Klinker MW, Marklein RA, Lo Surdo JL, Wei CH, Bauer SR. Morphological features of IFN-γ-stimulated mesenchymal stromal cells predict overall immunosuppressive capacity.. Proc Natl Acad Sci U S A 2017 Mar 28;114(13):E2598-E2607.
    doi: 10.1073/pnas.1617933114pmc: PMC5380055pubmed: 28283659google scholar: lookup
  38. Li Y, Lin F. Mesenchymal stem cells are injured by complement after their contact with serum.. Blood 2012 Oct 25;120(17):3436-43.
    pmc: PMC3482856pubmed: 22966167doi: 10.1182/blood-2012-03-420612google scholar: lookup
  39. Li Y, Fung J, Lin F. Local Inhibition of Complement Improves Mesenchymal Stem Cell Viability and Function After Administration.. Mol Ther 2016 Sep;24(9):1665-74.
    doi: 10.1038/mt.2016.142pmc: PMC5113108pubmed: 27377042google scholar: lookup
  40. Li Y, Wang W, Yang F, Xu Y, Feng C, Zhao Y. The regulatory roles of neutrophils in adaptive immunity.. Cell Commun Signal 2019 Nov 14;17(1):147.
    doi: 10.1186/s12964-019-0471-ypmc: PMC6854633pubmed: 31727175google scholar: lookup
  41. Mariñas-Pardo L, García-Castro J, Rodríguez-Hurtado I, Rodríguez-García MI, Núñez-Naveira L, Hermida-Prieto M. Allogeneic Adipose-Derived Mesenchymal Stem Cells (Horse Allo 20) for the Treatment of Osteoarthritis-Associated Lameness in Horses: Characterization, Safety, and Efficacy of Intra-Articular Treatment.. Stem Cells Dev 2018 Sep 1;27(17):1147-1160.
    doi: 10.1089/scd.2018.0074pubmed: 29978736google scholar: lookup
  42. Merkt W, Sturm P, Lasitschka F, Tretter T, Watzl C, Saure D, Hundemer M, Schwenger V, Blank N, Lorenz HM, Cerwenka A. Peripheral blood natural killer cell percentages in granulomatosis with polyangiitis correlate with disease inactivity and stage.. Arthritis Res Ther 2015 Nov 21;17:337.
    doi: 10.1186/s13075-015-0851-7pmc: PMC4654817pubmed: 26589807google scholar: lookup
  43. Mumaw JL, Schmiedt CW, Breidling S, Sigmund A, Norton NA, Thoreson M, Peroni JF, Hurley DJ. Feline mesenchymal stem cells and supernatant inhibit reactive oxygen species production in cultured feline neutrophils.. Res Vet Sci 2015 Dec;103:60-9.
    doi: 10.1016/j.rvsc.2015.09.010pubmed: 26679797google scholar: lookup
  44. Murphy KA. The complement system and innate immunity. In: Janeways immunobiology, 8th ed. New York: Garland Science; 2012.
  45. Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells.. J Immunol 2006 Aug 15;177(4):2080-7.
    doi: 10.4049/jimmunol.177.4.2080pubmed: 16887966google scholar: lookup
  46. Nguyen QT, Jacobsen TD, Chahine NO. Effects of Inflammation on Multiscale Biomechanical Properties of Cartilaginous Cells and Tissues.. ACS Biomater Sci Eng 2017 Nov 13;3(11):2644-2656.
    pmc: PMC5686563pubmed: 29152560doi: 10.1021/acsbiomaterials.6b00671google scholar: lookup
  47. Peeters CM, Leijs MJ, Reijman M, van Osch GJ, Bos PK. Safety of intra-articular cell-therapy with culture-expanded stem cells in humans: a systematic literature review.. Osteoarthritis Cartilage 2013 Oct;21(10):1465-73.
    doi: 10.1016/j.joca.2013.06.025pubmed: 23831631google scholar: lookup
  48. Pezzanite LM, Fortier LA, Antczak DF, Cassano JM, Brosnahan MM, Miller D, Schnabel LV. Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo.. Stem Cell Res Ther 2015 Apr 12;6(1):54.
    doi: 10.1186/s13287-015-0053-xpmc: PMC4414005pubmed: 25889095google scholar: lookup
  49. Prasanna SJ, Gopalakrishnan D, Shankar SR, Vasandan AB. Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially.. PLoS One 2010 Feb 2;5(2):e9016.
    doi: 10.1371/journal.pone.0009016pmc: PMC2814860pubmed: 20126406google scholar: lookup
  50. Proverbio D, Perego R, Baggiani L, Ferrucci F, Zucca E, Nobile F, Spada E. Prevalence of Ca Blood Type and Alloantibodies in a Population of Horses from Italy.. Animals (Basel) 2020 Jul 13;10(7).
    pmc: PMC7401544pubmed: 32668596doi: 10.3390/ani10071179google scholar: lookup
  51. Raffaghello L, Bianchi G, Bertolotto M, Montecucco F, Busca A, Dallegri F, Ottonello L, Pistoia V. Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche.. Stem Cells 2008 Jan;26(1):151-62.
    doi: 10.1634/stemcells.2007-0416pubmed: 17932421google scholar: lookup
  52. Ragni E, Viganò M, Rebulla P, Giordano R, Lazzari L. What is beyond a qRT-PCR study on mesenchymal stem cell differentiation properties: how to choose the most reliable housekeeping genes.. J Cell Mol Med 2013 Jan;17(1):168-80.
    doi: 10.1111/j.1582-4934.2012.01660.xpmc: PMC3823147pubmed: 23305553google scholar: lookup
  53. Ranera B, Antczak D, Miller D, Doroshenkova T, Ryan A, McIlwraith CW, Barry F. Donor-derived equine mesenchymal stem cells suppress proliferation of mismatched lymphocytes.. Equine Vet J 2016 Mar;48(2):253-60.
    doi: 10.1111/evj.12414pubmed: 25582202google scholar: lookup
  54. Rasmusson I, Le Blanc K, Sundberg B, Ringdén O. Mesenchymal stem cells stimulate antibody secretion in human B cells.. Scand J Immunol 2007 Apr;65(4):336-43.
    doi: 10.1111/j.1365-3083.2007.01905.xpubmed: 17386024google scholar: lookup
  55. Robbin MG, Wagner B, Noronha LE, Antczak DF, de Mestre AM. Subpopulations of equine blood lymphocytes expressing regulatory T cell markers.. Vet Immunol Immunopathol 2011 Mar 15;140(1-2):90-101.
    doi: 10.1016/j.vetimm.2010.11.020pubmed: 21208665google scholar: lookup
  56. Rowland AL, Miller D, Berglund A, Schnabel LV, Levine GJ, Antczak DF, Watts AE. Cross-matching of allogeneic mesenchymal stromal cells eliminates recipient immune targeting.. Stem Cells Transl Med 2021 May;10(5):694-710.
    doi: 10.1002/sctm.20-0435pmc: PMC8046071pubmed: 33369287google scholar: lookup
  57. Schnabel LV, Pezzanite LM, Antczak DF, Felippe MJ, Fortier LA. Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro.. Stem Cell Res Ther 2014 Jan 24;5(1):13.
    doi: 10.1186/scrt402pmc: PMC4055004pubmed: 24461709google scholar: lookup
  58. Shi K, Hayashida K, Kaneko M, Hashimoto J, Tomita T, Lipsky PE, Yoshikawa H, Ochi T. Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients.. J Immunol 2001 Jan 1;166(1):650-5.
    doi: 10.4049/jimmunol.166.1.650pubmed: 11123349google scholar: lookup
  59. Snyder L. Blood typing. In: Wilson D, editor. Clinical veterinary advisor: the horse. Pennsylvania: Elsevier Saunders; 2012.
  60. Tomlinson JE, Taberner E, Boston RC, Owens SD, Nolen-Walston RD. Survival Time of Cross-Match Incompatible Red Blood Cells in Adult Horses.. J Vet Intern Med 2015 Nov-Dec;29(6):1683-8.
    doi: 10.1111/jvim.13627pmc: PMC4895677pubmed: 26478135google scholar: lookup
  61. Ursini TL, Amelse LL, Elkhenany HA, Odoi A, Carter-Arnold JL, Adair HS, Dhar MS. Retrospective analysis of local injection site adverse reactions associated with 230 allogenic administrations of bone marrow-derived mesenchymal stem cells in 164 horses.. Equine Vet J 2019 Mar;51(2):198-205.
    doi: 10.1111/evj.12992pubmed: 29992618google scholar: lookup
  62. Vandenberghe A, Broeckx SY, Beerts C, Seys B, Zimmerman M, Verweire I, Suls M, Spaas JH. Tenogenically Induced Allogeneic Mesenchymal Stem Cells for the Treatment of Proximal Suspensory Ligament Desmitis in a Horse.. Front Vet Sci 2015;2:49.
    doi: 10.3389/fvets.2015.00049pmc: PMC4672201pubmed: 26664976google scholar: lookup
  63. Wang Y, Zhang A, Ye Z, Xie H, Zheng S. Bone marrow-derived mesenchymal stem cells inhibit acute rejection of rat liver allografts in association with regulatory T-cell expansion.. Transplant Proc 2009 Dec;41(10):4352-6.
    doi: 10.1016/j.transproceed.2009.08.072pubmed: 20005397google scholar: lookup
  64. Zhang Q, Fu L, Liang Y, Guo Z, Wang L, Ma C, Wang H. Exosomes originating from MSCs stimulated with TGF-β and IFN-γ promote Treg differentiation.. J Cell Physiol 2018 Sep;233(9):6832-6840.
    doi: 10.1002/jcp.26436pubmed: 29336475google scholar: lookup
  65. Zhou X, Jin N, Wang F, Chen B. Mesenchymal stem cells: a promising way in therapies of graft-versus-host disease.. Cancer Cell Int 2020;20:114.
    doi: 10.1186/s12935-020-01193-zpmc: PMC7137413pubmed: 32280306google scholar: lookup

Citations

This article has been cited 3 times.
  1. Cequier A, Vázquez FJ, Romero A, Vitoria A, Bernad E, García-Martínez M, Gascón I, Barrachina L, Rodellar C. The immunomodulation-immunogenicity balance of equine Mesenchymal Stem Cells (MSCs) is differentially affected by the immune cell response depending on inflammatory licensing and major histocompatibility complex (MHC) compatibility.. Front Vet Sci 2022;9:957153.
    doi: 10.3389/fvets.2022.957153pubmed: 36337202google scholar: lookup
  2. Honda N, Watanabe Y, Tokuoka Y, Hanajima R. Roles of microglia/macrophage and antibody in cell sheet transplantation in the central nervous system.. Stem Cell Res Ther 2022 Sep 11;13(1):470.
    doi: 10.1186/s13287-022-03168-5pubmed: 36089602google scholar: lookup
  3. Cequier A, Romero A, Vázquez FJ, Vitoria A, Bernad E, Fuente S, Zaragoza P, Rodellar C, Barrachina L. Equine Mesenchymal Stem Cells Influence the Proliferative Response of Lymphocytes: Effect of Inflammation, Differentiation and MHC-Compatibility.. Animals (Basel) 2022 Apr 11;12(8).
    doi: 10.3390/ani12080984pubmed: 35454231google scholar: lookup
Subscribe to our newsletter
Join 99,383 horse owners like you who receive our email updates on horse health and nutrition.